Dynavax Technologies Corp DVAX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:51 AM EST
8.00quote price arrow down-0.49 (-5.77%)
Volume
1,508
Close
8.49quote price arrow down-0.15 (-1.74%)
Volume
2,997,133
52 week range
1.80 - 12.44

...

Loading . . .

KEY STATS

  • Open8.60
  • Day High8.83
  • Day Low8.31
  • Prev Close8.49
  • 52 Week High12.44
  • 52 Week High Date07/20/20
  • 52 Week Low1.80
  • 52 Week Low Date03/16/20
  • Market Cap961.58M
  • Shares Out113.26M
  • 10 Day Average Volume4.64M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • 1 Year % Change98.83

RATIOS/PROFITABILITY

  • EPS (TTM)-0.78
  • P/E (TTM)-10.91
  • Fwd P/E (NTM)-33.56
  • EBITDA (MRQ)-66.153M
  • ROE (MRQ)-224.65%
  • Revenue (MRQ)46.55M
  • Gross Margin (MRQ)70.12%
  • Net Margin (MRQ)-161.63%
  • Debt To Equity (MRQ)306.36%

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Dynavax Technologies Corp News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an...
Andrew Hack M.D., Ph.D.
Chairman
Ryan Spencer
Chief Executive Officer
David Novack
President
Michael Ostrach J.D.
Chief Financial Officer
Justin Burgess
Chief Accounting Officer
Address
2100 POWELL STREET, SUITE 900
Emeryville, CA
94608
United States